Overview
On 16 November 2004, orphan designation (EU/3/04/244) was granted by the European Commission to BCG (Europe) Ltd, United Kingdom, for alpha-one antitrypsin (inhalation use) for the treatment of the emphysema secondary to congenital alpha-1-antitrypsin deficiency.
The sponsorship was transferred to The Weinberg Group LLC, United Kingdom, in July 2007, then to The Weinberg Group Limited, United Kingdom, in April 2009 and subsequently to Innovative Drug European Associates Limited, United Kingdom, in May 2011.
In December 2012, Innovative Drug European Associates Limited changed name to IDEA Innovative Drug European Associates Limited.
The sponsorship was transferred
- to The Weinberg Group LLC, United Kingdom, in July 2007,
- to The Weinberg Group Limited, United Kingdom, in April 2009,
- to Innovative Drug European Associates Limited, United Kingdom, in May 2011 and
- to Kamada BioPharma Limited, United Kingdom, in February 2016.
The sponsorship was transferred to Kamada Ireland Limited, Ireland in April 2019.
Key facts
Active substance |
Alpha-1 antitrypsin
|
Intended use |
Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/04/244
|
Date of designation |
16/11/2004
|
Sponsor |
Kamada Ireland Limited |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: